コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 ddC (300 nM) reduced mitochondrial DNA levels from appro
2 ddC also targeted leukemic stem cells in secondary AML x
3 ddC and saline eyes were treated four times daily for 7
4 ddC demonstrated potent antiadenovirus activity in vitro
5 ddC is a selective inhibitor of the mitochondrial DNA po
6 ddC treatment inhibited mtDNA replication, oxidative pho
7 ddC was more potent than cidofovir for seven of nine ser
8 ddC was preferentially activated in AML cells compared w
14 g 3'-azido-2',3'-ddA (AZddA), 3'-azido-2',3'-ddC (AZddC), 3'-azido-2',3'-ddG (AZddG), AZT, and 3'-azi
15 ntrast, the rate of exonuclease removal of a ddC chain-terminated DNA occurs at least 2 orders of mag
17 ic treatment with the anti-retroviral agent, ddC (Zalcitabine) with or without the concomitant delive
24 (5-fluoro-2',3'-dideoxy-3'-thiacytidine) and ddC (2',3'-dideoxycytidine) were added to the cultures b
25 of the lymphocytes from control thymuses and ddC-induced lymphomas were positive for Thy-1.2 (pan-T),
27 eralgesia caused by HIV/AIDS antiretroviral [ddC (2',3'-dideoxycytidine)] and anticancer (oxaliplatin
31 prevents the development of neurotoxicity by ddC, as judged by amelioration of ddC-induced "neuritic
35 vels by treating with 2',3'-dideoxycytidine (ddC) and subsequently allowed recovery to normal levels
37 analogs, Zalcitabine (2',3'-dideoxycytidine (ddC)) and Lamivudine (beta-d-(+)-2',3'-dideoxy-3'-thiacy
38 deoxythymidine (D4T), 2',3'-dideoxycytidine (ddC), (-)-beta-L-2',3'-dideoxy-3'-thiacytidine (3TC), (-
39 tion caused by beta-d-2',3'-dideoxycytidine (ddC), 2',3'-didehydro-2',3'-dideoxythymidine, and 2',3'-
40 nalogs such as beta-D-2',3'-dideoxycytidine (ddC), beta-2'-fluoro-5-methyl-arabinofuranosyluracil (FM
41 ed a nucleoside analog 2'3'-dideoxycytidine (ddC), which is phosphorylated to the activated antimetab
43 We show that among the dideoxynucleosides, ddC appears to be the most neurotoxic, followed by ddI a
45 ocular administration are needed to evaluate ddC as a topical antiviral treatment for adenoviral ocul
50 nsitivity to mechanical stimuli in the gp120+ddC model and reversal of some measures of thigmotaxis.
52 ion of L-OddC, L-SddC, L-Fd4C, L-FMAU, and L-ddC were compared with D-deoxynucleoside analogs, AraC,
53 Immunohistochemical studies revealed little ddC-associated alteration in DRG phenotype, as compared
54 within 24 hr, which is in contrast to 300 nM ddC, which had no effect on cell growth for the first 4
55 he 50% inhibitory concentrations (IC(50)) of ddC and cidofovir were determined using standard plaque-
56 oxicity by ddC, as judged by amelioration of ddC-induced "neuritic pruning," neuronal mitochondrial d
57 igh correlation between the internal dose of ddC and the incidence of thymic lymphoma in both mouse m
61 phosphorylated metabolites, whereas that of ddC and the L-deoxycytidine analogs may not involve dCMP
63 ats treated with perineural HIV-gp120 and/or ddC and there is a reduction in intraepidermal nerve fib
64 tment regimens that included ddI plus AZT or ddC plus AZT in situations in which the T215Y and/or M41
67 riptase-resistant, azidothymidine-resistant, ddC/ddI-resistant, nivirapine-resistant, and other clini
69 s vary more than 500,000-fold for the series ddC > ddA (ddI) > 2',3'-didehydro-2',3'-dideoxythymidine
73 ein was detected in only 20% (23/115) of the ddC-induced lymphomas with mostly minimal expression in
74 d as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested significantly higher affinity fo
76 he delayed increase in lactate observed with ddC exposure, CldAdo-treated cells exhibited a 2-2.4-fol
79 n animal models of human AML, treatment with ddC decreased mtDNA, electron transport chain proteins,
81 e (Ara-C), zidovudine (AZT) and zalcitabine (ddC)-we show that TDP1 is capable of removing the covale
83 ated with zidovudine (AZT) plus zalcitabine (ddC) and didanosine (ddI) develop AZT resistance mediate
84 rs of magnitude in the sequence zalcitabine (ddC) > didanosine (ddI metabolized to ddA) > stavudine (
86 he findings support the clinical use of Zdv, ddC, ddI, and d4T but not of 3TC for the antiretroviral
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。